Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

PHASE2CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

March 31, 2010

Primary Completion Date

March 31, 2011

Study Completion Date

June 30, 2012

Conditions
Primary Systemic Amyloidosis
Interventions
DRUG

bortezomib

1.3 mg/m\^2, by IV on days 1, 8 and 15 every 28 days

DRUG

cyclophosphamide

300 mg/m\^2, orally, on days 1, 8, 15 \& 22 every 28 days.

DRUG

dexamethasone

40 mg, orally, on days 1, 8, 15 \& 22 every 28 days

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT01072773 - Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis | Biotech Hunter | Biotech Hunter